Can airway cell clues predict a rare lung disease in children?

NCT ID NCT06140901

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study looks at children aged 1 month to 6 years who are hospitalized with a severe respiratory infection caused by adenovirus or rhinovirus. The goal is to compare the airway cells of those who develop a rare lung condition called post-infectious bronchiolitis obliterans (PIBO) with those who do not. Researchers will collect nasal samples and, in children who develop PIBO, also take bronchial biopsies and washings to examine the cells' shape and function. The hope is to understand why some children get PIBO and to find early signs that could lead to faster diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Nasal swab and brushing, bronchial biopsies, and bronchoalveolar lavage (diagnostic procedures)
What this could lead to
If successful, this could help identify early markers that predict which children with adenovirus or rhinovirus infections will develop bronchiolitis obliterans, potentially leading to earlier diagnosis and better management.
What could go wrong
This is a small pilot study, so findings may not be definitive or generalizable. The procedures are invasive and carry risks, and the study does not test a treatment, so it may not directly change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • APHM

    RECRUITING

    Marseille, 13000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.